This is a tool to identify specific Alzheimer’s clinical trials. Just click on the start button and enter the information as prompted. You will be provided with a list of the trials within your geographic area.
Seeking caregivers for participation in survey regarding financial exploitation
Are you a caregiver to a patient with a neurodegenerative condition? You are invited to participate in a survey examining the prevalence of financial exploitation and scams in those with neurodegenerative conditions such as dementia. This is a survey study
- Survey can be completed online or via telephone
- Estimated completion time = ~20 minutes
- All analysis will be conducted at the group level
If interested, please contact: Preeti Sunderaraman, PhD at email@example.com
IRB-AAAT1976 (Y01M00) IRB Exemption Date: 09/03/2020
Take part in our clinical study
The LUCIDITY study is sponsored by TauRx Therapeutics Ltd., a leader in neurodegenerative disease research. As you may be aware, there is an urgent need for better treatments for Alzheimer’s disease (AD) as current therapies help with the symptoms of AD but do not stop the disease from progressing.
If you or a loved one are experiencing memory loss, or have been diagnosed with Mild Cognitive Impairment (MCI or MCI-AD), Probable/Early Alzheimer’s disease, or Mild-Moderate Alzheimer's disease, you or a loved one may be eligible to participate in our clinical research study.
Clinical Trial Sites in New York City
These Alzheimer’s clinical trial sites in New York City welcome individuals with memory issues to make an appointment for evaluation. After screening and initial testing, for qualifying candidates the site will suggest appropriate trials for consideration.
1305 York Avenue; Box 305
New York, NY 10065
View Full List
Other Research Trials in New York City
NYU Langone Health
The NYU Langone Vaccine Center is seeking healthy adult volunteers who are interested in participating in clinical research for a COVID-19 vaccine study.
For more information, call 646-501-9854 or email: COVID_vaccine_study@nyulangone.org
New Clinical Study Currently Enrolling People with Memory Loss and Elevated Blood Sugar
The Elevage study (NCT03980730) is being conducted to evaluate the efficacy and safety of azeliragon in patients who are experiencing memory loss and have elevated blood sugar or Type 2 Diabetes.
To qualify for participation in the study you must:
- Be 50-85 years of age (inclusive)
- Currently be taking medication for memory loss (including Aricept (donepezil), Exelon (rivastigmine), Razadyne or Reminyl (galantamine) and/or Namenda or Ebixa (memantine), etc.)
- Have elevated blood sugar (A1c 6.5% to 9.5%)
- Have a reliable caregiver/study partner
To learn more, click here.
Join a Research Study: Neurodegeneration-Associated Psychiatric Syndromes
Principal Investigator: Edward Huey, M.D.
Seeking participants for an observational research study looking at how dementias (like Alzheimer’s disease) can affect mood and behavior.
- Participation involves coming in with a study partner (someone who knows you well) for one voluntary, 4-5 hour visit to answer questions about recent mood and emotions and complete an MRI scan
- Participants will be compensated $50-$100
This study is recruiting participants with dementia, including:
- People who have been diagnosed with Alzheimer’s disease
- Who are between 40-90 years old,
- And who speak English or Spanish.
How do I participate?
If you are interested in becoming involved in this study or learning more, please contact the research team at (212) 305-3187 or HueyResearchTeam@cumc.columbia.edu
Weill Cornell Medicine - Family Caregiver Research Study
Do you care for someone with dementia and pain? Are you a family member or unpaid caregiver?
If so, we want to learn from you! You are invited to participate in a one-time, 20-30 minute in person or phone interview. To thank you for your time, you will be provided with a $15 gift card after completing the interview.
For more information or to participate, please contact Dr. Riffin: 212-746-7317 or firstname.lastname@example.org
Care Partners Program
If you are caring for a loved one with Alzheimer’s or other dementias, you might be eligible to take part in a research study that Weill Cornell Medicine is conducting. You will learn strategies to reduce stress, enhance caregiving skills, and improve overall well-being. Your loved one will receive cognitive training or mental stimulating exercises.
The study has a duration of 12 months. You and your loved one can participate from the comfort of your home at no cost. You will receive a laptop with Wi-fi capability during study participation to access study-related material and content. You will also receive financial compensation for your time and effort.
For more information, please contact us at:
(646) 962-7141 or AgingBehavioralRsrch@med.cornell.edu
Seeking individuals with Alzheimer’s disease who experience agitation
The Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD) study is a 12-week trial of escitalopram taking place at Memory Disorders Clinic at New York State Psychiatric Institute.
The S-CitAD Research Study is looking for volunteers who:
- Have been diagnosed with Alzheimer’s disease
- Experience feelings of irritability, restlessness, frustration, or anger
- Have a study partner who can participate in the study
All participants receive: Free parking at each visit, Psychosocial counseling provided to all eligible participants, All visit procedures administered at no cost.
Call 646-774-8671 for more information.
Survey for Caregivers
Are you currently providing care to someone with dementia? Are you employed or were you employed at any point while caring for your friend, family member, or neighbor with Alzheimer’s disease or Dementia? If you answered ‘yes’, then we would love to hear from you!
Researchers at the University at Albany School of Public Health are looking for interested individuals to participate in a study that seeks to understand the experiences of working caregivers. This anonymous survey should take about 10-15 minutes of your time, and can be accessed at the following link:
Participate in a research project on Alzheimer's and Caregiving
The purpose of this project is to identity the types of decisions that caregivers face as their family member or friend progresses through the stages of Alzheimer's.
Cognite Early Stage Alzheimer's Clinical Trial
Imagine making an impact
Consider taking part in a clinical trial that is currently enrolling to treat for early stage Alzheimer’s disease
What is the Cognite Trial?
The Cognite Alzheimer’s Clinical Trial is enrolling men and women who have signs of early stage Alzheimer’s disease. The clinical trial is evaluating whether an investigational combined treatment slows down, arrests, or reverses early stage Alzheimer’s disease.
To qualify, participants must:
- Be between 55 and 79 years old
- Have at least 8 years of education
- Have noticed, or have had a loved one notice, changes in your memory
- Have noticed changes in their normal, everyday behavior
- Attend all study visits with a study partner with whom the
participant has frequent contact
- Be in good general health
Are you or someone you know experiencing memory loss? Are you or someone you know having trouble retaining information? This may be an indication of early stage Alzheimer’s disease, which is a type of dementia that causes problems with an individual’s memory, thinking, and behavior.
For more information:
646-678-4196 | cognitetrial.com
Treatment of Psychosis and Agitation in Alzheimer’s Disease
This research study, funded by the NIH, involves a 12-week double-blind treatment trial in which outpatients with Alzheimer’s disease (age 55-95 years) who have agitation/aggression with or without psychosis (hallucinations or delusions) will receive either low-dose lithium or placebo. Patients are allowed to receive other specific psychiatric medications if needed during the study, and will be closely monitored by physicians who specialize in memory disorders. Patients will receive open treatment with lithium, if clinically indicated, after completing the 12-week double blind trial.
For more information, please contact Jesse Strickler at (646) 774-8668 or email@example.com.
ClinicalTrials.gov Identifier: NCT02129348